Cartesian Therapeutics Inc
RNAC12.360USD
+0.030+0.24%
交易中 （美東）報價延遲15分鐘
320.57M總市值
虧損本益比TTM
關於 Cartesian Therapeutics Inc 公司
Cartesian Therapeutics, Inc. 是一家臨牀階段公司。該公司致力於開發用於治療自身免疫性疾病的信使核糖核酸 (mRNA) 細胞療法。該公司正在利用其專有技術和製造平臺 RNA Armory 開發用於治療自身免疫性疾病的 mRNA 細胞療法。其主要資產 e，Descartes-08，是一種針對 B 細胞成熟抗原 (BCMA) 的自體 mRNA 嵌合抗原受體 T 細胞療法 (CAR-T)，該公司正在開發用於治療自身免疫性疾病。Descartes-08 正處於 II 期臨牀開發階段。Descartes-15 是下一代自體抗 BCMA mRNA CAR-T。利用其專有技術和製造平臺，該公司設計了 Descartes-15，使其在多次抗原暴露後比 Descartes-08 更能抵抗 CAR 的回收。該公司正在開發 Descartes-33，以提供針對自身免疫發病機制中關鍵驅動因素的治療性蛋白質組合。
公司簡介
公司代碼RNAC
公司名稱Cartesian Therapeutics Inc
上市日期Jun 22, 2016
CEODr. Carsten Brunn, Ph.D.
員工數量66
證券類型Ordinary Share
年結日Jun 22
公司地址7495 New Horizon Way
城市FREDERICK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編21703
電話13013488698
網址https://www.cartesiantherapeutics.com/
公司代碼RNAC
上市日期Jun 22, 2016
CEODr. Carsten Brunn, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Independent Director
Independent Director
3.82K
-14.03%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
--
-100.00%
Dr. Michael S. Singer, M.D., Ph.D.
Dr. Michael S. Singer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Independent Director
Independent Director
3.82K
-14.03%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月23日 週三
更新時間: 7月23日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Springer Timothy A
33.28%
Seven One Eight Three Four Irrevocable Trust
17.55%
Fidelity Management & Research Company LLC
9.02%
MPM BioImpact LLC
3.05%
Singer (Michael S.)
2.72%
Other
34.38%
持股股東
持股股東
佔比
Springer Timothy A
33.28%
Seven One Eight Three Four Irrevocable Trust
17.55%
Fidelity Management & Research Company LLC
9.02%
MPM BioImpact LLC
3.05%
Singer (Michael S.)
2.72%
Other
34.38%
股東類型
持股股東
佔比
Individual Investor
39.94%
Corporation
20.08%
Investment Advisor
18.12%
Investment Advisor/Hedge Fund
5.70%
Hedge Fund
1.47%
Research Firm
0.19%
Insurance Company
0.10%
Bank and Trust
0.10%
Pension Fund
0.03%
Other
14.26%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
206
22.28M
85.84%
-1.26M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
2023Q2
261
3.72M
72.70%
-649.68K
2023Q1
272
3.43M
67.38%
-196.84K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Springer Timothy A
8.64M
33.28%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.55%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.34M
9.02%
-83.30K
-3.44%
Mar 31, 2025
MPM BioImpact LLC
790.78K
3.05%
+69.64K
+9.66%
Mar 31, 2025
Singer (Michael S.)
707.06K
2.72%
-623.00
-0.09%
Apr 14, 2025
TAS Partners, L.L.C.
656.51K
2.53%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
608.03K
2.34%
+1.49K
+0.25%
Mar 31, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
-8.96K
-1.57%
Mar 31, 2025
The Vanguard Group, Inc.
503.54K
1.94%
+74.06K
+17.24%
Mar 31, 2025
Kalayoglu (Murat)
502.42K
1.94%
-8.88K
-1.74%
Apr 14, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ALPS Medical Breakthroughs ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.91%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Micro-Cap ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Global X Russell 2000 Covered Call ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ALPS Medical Breakthroughs ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
公告日期
類型
比率
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
